Patent intelligence · US
US 10111925
Formulations comprising plant extracts
Formulations comprising plant extracts
Patent details — US 10111925
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 30, 2018
- Expiration
- Oct 25, 2038
- Applicant
- MONTERO GIDA SANAYI VE TICARET A.S.
- Claims
- 22
- CPC classes
- A61K, A61K35/644, A61K36/185, A61K36/25
Quick answer
US 10111925 (Formulations comprising plant extracts) is held by MONTERO GIDA SANAYI VE TICARET A.S.. Status: granted. Granted Oct 30, 2018. Expires Oct 25, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MONTERO GIDA SANAYI VE TICARET A.S.
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61K, A61K35/644, A61K36/185, A61K36/25, A61K36/28, A61K36/484
More from MONTERO GIDA SANAYI VE TICARET A.S.
Related pharmaceutical patents in our USPTO index.
-
US 12391663
Isoindolinone compounds
granted -
US 12378199
Rigidified pentadentate chelating agents useful for the [Al18F]2+ labelling of biomolecules
granted -
US 12280029
Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
granted -
US 12263143
Ionic channel modulation as a method for treating tumors through inflammasome activation
granted -
US 12257247
Targeted degradation of VAV1
granted -
US 12214218
Perfusion modulated tumor dose sculpting with single dose radiotherapy
granted -
US 12070628
Low energy immune priming for treating cancer and metastasis
granted -
US 12011619
Low intensity focused ultrasound for treating cancer and metastasis
granted
Frequently asked questions
What is US patent 10111925?
US 10111925 (Formulations comprising plant extracts) is held by MONTERO GIDA SANAYI VE TICARET A.S.. Status: granted. Granted Oct 30, 2018. Expires Oct 25, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10111925?
MONTERO GIDA SANAYI VE TICARET A.S. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 72 pharmaceutical patents for this assignee.
When does US 10111925 expire?
Our index shows an expiration date of Oct 25, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.